Full-Spectrum EV Platform. Precision Biomanufacturing from Source to Specification.
BioThera Solutions operates a full-stack plant-derived extracellular vesicle (EV/exosome) biomanufacturing platform — from upstream botanical isolation to downstream MISEV2023-compliant characterization, designed for consistency, traceability, and scalability.
What Are Extracellular Vesicles (EVs / Exosomes)?
Extracellular vesicles (EVs/exosomes) are nanoscale, membrane-bound particles naturally released by virtually all cell types as part of normal cellular communication. They range from approximately 30 to 200 nm in diameter and carry a complex molecular cargo — including proteins, lipids, nucleic acids (such as miRNA and mRNA), and bioactive signaling molecules.
EVs function as endogenous intercellular messengers: they are taken up by recipient cells, where their cargo can modulate gene expression, influence inflammatory signaling, and support cellular repair mechanisms. This biological activity makes EVs an area of substantial scientific and commercial interest across medicine and consumer health.
In skin biology specifically, EVs derived from botanical sources have been shown in the peer-reviewed literature to support antioxidant defenses, attenuate inflammatory pathways, and contribute to regenerative signaling in keratinocyte and fibroblast populations. No therapeutic claims are made — the mPDEV Serum is a cosmetic product.
Note: The term "exosome" is colloquially used in the broader market but is not precise under current ISEV/MISEV2023 guidelines, which recommend "extracellular vesicle" (EV) as the primary scientific descriptor unless intracellular endosomal origin is experimentally confirmed. BioThera uses "EV" as its primary scientific term throughout all materials.
EV composition and corona structure vary by source cell type, isolation method, and biological environment.
How Does BioThera Solutions Manufacture Plant-Derived EVs?
BioThera Solutions uses a validated, closed-loop biomanufacturing workflow — encompassing upstream botanical sourcing, EV isolation, and downstream particle characterization — producing plant-derived EVs to MISEV2023 specifications. The process is engineered for batch-to-batch reproducibility, full traceability, and scalability from research-grade to commercial-grade output.
Our EV isolation and purification process is proprietary and IP-protected. Process details are not disclosed publicly. What we can confirm:
- Designed for reproducibility and scalability from the ground up
- Every production batch undergoes standardized analytical characterization
- Ships frozen — cold-chain protocols maintained throughout handling and distribution
- Manufacturing trajectory aligned toward GMP and ISO compliance
Our Core Moat
We know how to produce industrial quantities of EVs at scale — across source modalities. Our biomanufacturing workflow is the infrastructure the field has been missing: reproducible, standardized, and built from the ground up to accommodate plant-derived EVs today and broader mammalian EV source modalities as the platform matures.
Quality Control Framework
Nanoparticle Tracking Analysis (NTA)
Particle concentration and size distribution verified per batch — the gold standard for EV characterization under MISEV2023.
Certificate of Analysis (CoA)
Batch-level documentation issued for every production run.
Cold-Chain Handling
Temperature-controlled from manufacturing through delivery. Product ships frozen to ensure EV bioactivity is fully preserved upon arrival.
MISEV2023-Compliant Characterization
Characterization approach fully compliant with the Minimal Information for Studies of EVs (MISEV2023) guidelines published by the International Society for Extracellular Vesicles (ISEV) — the global field standard.
Why Plant-Derived EVs?
BioThera's platform is built on plant-derived EVs — a deliberate scientific and strategic choice that is cost-effective, 100% sustainable, and entirely ethical.
Cross-Kingdom Biological Communication
The capacity of plant-derived EVs to interact with and influence mammalian cellular processes represents an emerging and scientifically important area of EV research. This cross-kingdom biological communication underpins our current platform — and informs the broader multi-modality EV commercialization strategy BioThera is building toward.
Abundant Botanical Biomass
Plant biomass provides an abundant, low-cost, and renewable upstream resource — no animal or human donor material required for our current product line. This supports scalable, consistent upstream production at a fraction of the cost of mammalian cell culture systems.
Streamlined, Cost-Efficient Production
Plant-derived EV production eliminates the bioreactor complexity, contamination risk, and regulatory overhead associated with mammalian cell culture — making it the most commercially viable entry point for industrial-scale EV manufacturing. This production knowledge base is designed to evolve as BioThera expands across EV source modalities.
Hypo-Allergenic Safety Profile
Extensive use of botanical actives in cosmetics provides a well-characterized safety baseline. Plant-derived EVs exhibit a biocompatible profile appropriate for topical dermocosmetic use.
Biologically Active Cargo
Plant EVs carry biologically relevant cargo — including small RNA species and signaling molecules — capable of influencing gene-regulatory and cellular signaling pathways in human skin cells.
What Bioactive Cargo Do Plant-Derived EVs Carry?
Proteomics characterization of BioThera Solutions's plant-derived EV (mPDEV) fraction identified proteins distributed across three functional classes: antioxidant-associated, anti-inflammatory-associated, and wound-healing/regenerative-associated. These payload classes are consistent with the well-documented biological profile of Aloe barbadensis across decades of peer-reviewed literature.
BioThera has identified three distinct bioactive payload classes in our plant-derived EVs, confirmed by proteomics analysis.
Antioxidant Payload
Antioxidant-active molecules — including plant-derived phenolic compounds and free radical scavengers — confirmed by proteomics. These attenuate oxidative stress in skin cell populations and support cellular defense mechanisms.
Anti-Inflammatory Payload
Signaling molecules confirmed by proteomics that modulate pro-inflammatory cytokine pathways in keratinocyte and fibroblast populations — attenuating surface inflammation without pharmacological intervention.
Wound-Healing / Regenerative Payload
Growth factor-associated molecules and miRNA species confirmed by proteomics that support regenerative signaling — including pathways involved in collagen synthesis, keratinocyte migration, and extracellular matrix remodeling.
Bioactive payload characterization conducted by proteomics and in accordance with MISEV2023 guidelines. No therapeutic claims are made — the mPDEV Serum is a cosmetic product regulated under Health Canada Cosmetic Regulations (C.R.C., c. 869).
The mPDEV (Exosome) Serum
BioThera's flagship dermocosmetic — plant-derived extracellular vesicles, precision-manufactured and clinician-ready. Full formulation details, ingredient rationale, CoA information, and early access waitlist.
View the ProductHow Do Plant-Derived EVs Interact with Human Skin?
Current scientific evidence supports EV surface and epidermal interaction as the primary mechanism by which topically applied plant-derived EVs may influence skin biology. BioThera Solutions presents an evidence-stratified model distinguishing well-supported surface interactions from plausible follicular routes, while explicitly noting that trans-stratum corneum passive diffusion has not been demonstrated for EV-sized particles (30–200 nm).
Extracellular vesicles are proposed to interact with human skin through multiple pathways — each associated with a distinct level of experimental support. This model distinguishes well-supported surface and epidermal interactions from plausible follicular penetration. Trans-stratum corneum passive diffusion has not been demonstrated for EV-sized particles (30–200 nm) and is not represented as a viable pathway. No mechanism depicted is clinically confirmed.
Pathway Evidence Levels
Evidence-stratified pathway model — no mechanism is clinically confirmed. This illustration maps two proposed interaction pathways with experimental support, and one that has not been demonstrated. Surface and epidermal interaction (stratum corneum surface, keratinocytes) is well-supported in the botanical EV literature. Follicular penetration via the hair follicle shaft and sebaceous duct is a plausible and increasingly studied route for nanoscale particles. Trans-stratum corneum passive diffusion has not been demonstrated for particles in the EV size range (30–200 nm) — they exceed classical passive diffusion thresholds (~500 Da) by several orders of magnitude, and this route is not represented as viable.
Anatomical accuracy & site-of-effect framing. Layer proportions are calibrated to H&E histological reference standards. The epidermis is rendered at 3× its true relative scale. Vasculature is shown in longitudinal view; hair follicle, sebaceous gland, eccrine sweat gland, and dermal innervation are anatomically positioned. EV opacity attenuates with depth to reflect decreasing penetration confidence. The dermis is marked as the proposed site of biological effect — surface interactions may initiate signalling cascades that propagate to deeper dermal cell populations, independent of whether EVs physically traverse the stratum corneum.